Maze Therapeutics, Inc.

As the son of two scientists, Kevin Parker, 31, never wanted to be a scientist. “I did not grow up thinking that I wanted to be a scientist,” he said. “Both of my parents are PhDs in organic chemistry

There were six initial public offerings by biopharmaceutical companies on Western stock exchanges during the first quarter of 2025, up from four in the fourth quarter of 2024, but all of the IPOs occu

Sionna Therapeutics has multiple drug candidates in the clinic and an ambition to improve cystic fibrosis treatment beyond what Vertex Therapeutics has achieved with its blockbuster portfolio of cysti

Biotech IPOs staged a moderate recovery in 2024 but a muted end to the year showed how fragile the market remains for companies looking to launch. Full year data shows 26 companies debuted on US excha